BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 27350604)

  • 1. Targeted proteomics identifies liquid-biopsy signatures for extracapsular prostate cancer.
    Kim Y; Jeon J; Mejia S; Yao CQ; Ignatchenko V; Nyalwidhe JO; Gramolini AO; Lance RS; Troyer DA; Drake RR; Boutros PC; Semmes OJ; Kislinger T
    Nat Commun; 2016 Jun; 7():11906. PubMed ID: 27350604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of prostate-enriched proteins by in-depth proteomic analyses of expressed prostatic secretions in urine.
    Principe S; Kim Y; Fontana S; Ignatchenko V; Nyalwidhe JO; Lance RS; Troyer DA; Alessandro R; Semmes OJ; Kislinger T; Drake RR; Medin JA
    J Proteome Res; 2012 Apr; 11(4):2386-96. PubMed ID: 22339264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of differentially expressed proteins in direct expressed prostatic secretions of men with organ-confined versus extracapsular prostate cancer.
    Kim Y; Ignatchenko V; Yao CQ; Kalatskaya I; Nyalwidhe JO; Lance RS; Gramolini AO; Troyer DA; Stein LD; Boutros PC; Medin JA; Semmes OJ; Drake RR; Kislinger T
    Mol Cell Proteomics; 2012 Dec; 11(12):1870-84. PubMed ID: 22986220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer.
    Sequeiros T; Rigau M; Chiva C; Montes M; Garcia-Grau I; Garcia M; Diaz S; Celma A; Bijnsdorp I; Campos A; Di Mauro P; Borrós S; Reventós J; Doll A; Paciucci R; Pegtel M; de Torres I; Sabidó E; Morote J; Olivan M
    Oncotarget; 2017 Jan; 8(3):4960-4976. PubMed ID: 27903962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of prostate cancer biomarkers in urinary exosomes.
    Øverbye A; Skotland T; Koehler CJ; Thiede B; Seierstad T; Berge V; Sandvig K; Llorente A
    Oncotarget; 2015 Oct; 6(30):30357-76. PubMed ID: 26196085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Global and Targeted Proteomics of Prostate Cancer Cell Secretome: Combination of 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry and In Silico Selection Selected Reaction Monitoring Analysis.
    Nurdin A; Hoshi Y; Yoneyama T; Miyauchi E; Tachikawa M; Watanabe M; Terasaki T
    J Pharm Sci; 2016 Nov; 105(11):3440-3452. PubMed ID: 27665127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Proteome of Primary Prostate Cancer.
    Iglesias-Gato D; Wikström P; Tyanova S; Lavallee C; Thysell E; Carlsson J; Hägglöf C; Cox J; Andrén O; Stattin P; Egevad L; Widmark A; Bjartell A; Collins CC; Bergh A; Geiger T; Mann M; Flores-Morales A
    Eur Urol; 2016 May; 69(5):942-52. PubMed ID: 26651926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent progress in urinary proteome analysis for prostate cancer diagnosis and management.
    Frantzi M; Latosinska A; Merseburger AS; Mischak H
    Expert Rev Mol Diagn; 2015; 15(12):1539-54. PubMed ID: 26491818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomics-based signature for human benign prostate hyperplasia and prostate adenocarcinoma.
    Alaiya AA; Al-Mohanna M; Aslam M; Shinwari Z; Al-Mansouri L; Al-Rodayan M; Al-Eid M; Ahmad I; Hanash K; Tulbah A; Bin Mahfooz A; Adra C
    Int J Oncol; 2011 Apr; 38(4):1047-57. PubMed ID: 21305254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein signatures to distinguish aggressive from indolent prostate cancer.
    Garcia-Marques F; Liu S; Totten SM; Bermudez A; Tanimoto C; Hsu EC; Nolley R; Hembree A; Stoyanova T; Brooks JD; Pitteri SJ
    Prostate; 2022 Apr; 82(5):605-616. PubMed ID: 35098564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging proteomics biomarkers and prostate cancer burden in Africa.
    Adeola HA; Blackburn JM; Rebbeck TR; Zerbini LF
    Oncotarget; 2017 Jun; 8(23):37991-38007. PubMed ID: 28388542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
    Sardana G; Jung K; Stephan C; Diamandis EP
    J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Urine as a source for clinical proteome analysis: from discovery to clinical application.
    Rodríguez-Suárez E; Siwy J; Zürbig P; Mischak H
    Biochim Biophys Acta; 2014 May; 1844(5):884-98. PubMed ID: 23831154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary proteomic profiles of prostate cancer with different risk of progression and correlation with histopathological features.
    Bergamini S; Caramaschi S; Monari E; Martorana E; Salviato T; Mangogna A; Balduit A; Tomasi A; Canu P; Bellei E
    Ann Diagn Pathol; 2021 Apr; 51():151704. PubMed ID: 33460996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In silico verification and parallel reaction monitoring prevalidation of potential prostate cancer biomarkers.
    Adeola HA; Calder B; Soares NC; Kaestner L; Blackburn JM; Zerbini LF
    Future Oncol; 2016 Jan; 12(1):43-57. PubMed ID: 26615920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [DiaPat test for prostate cancer diagnosis].
    Semjonow A
    Urologe A; 2007 Oct; 46(10):1428. PubMed ID: 17846740
    [No Abstract]   [Full Text] [Related]  

  • 18. Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy.
    Fredolini C; Liotta LA; Petricoin EF
    Crit Rev Clin Lab Sci; 2010; 47(3):125-38. PubMed ID: 20858067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer genetics-guided discovery of serum biomarker signatures for diagnosis and prognosis of prostate cancer.
    Cima I; Schiess R; Wild P; Kaelin M; Schüffler P; Lange V; Picotti P; Ossola R; Templeton A; Schubert O; Fuchs T; Leippold T; Wyler S; Zehetner J; Jochum W; Buhmann J; Cerny T; Moch H; Gillessen S; Aebersold R; Krek W
    Proc Natl Acad Sci U S A; 2011 Feb; 108(8):3342-7. PubMed ID: 21300890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.